MENU
Showcases Stock ranks Forex

Verastem Inc (VSTM)
1.28  0.09 (7.56%) 08-08 16:00
Open: 1.17 Pre. Close: 1.19
High: 1.2994 Low: 1.16
Volume: 2,041,313 Market Cap: 239M
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 1.3 - 1.305 1.305 - 1.309
Low: 1.148 - 1.153 1.153 - 1.158
Close: 1.271 - 1.279 1.279 - 1.286
Stock Technical Analysis
Overall:     
Target: Six months: 1.52
One year: 1.77
Support: Support1: 1.15
Support2: 1.05
Resistance: Resistance1: 1.30
Resistance2: 1.52
Pivot: 1.15
Moving Averages: MA(5): 1.16
MA(20): 1.15
MA(100): 1.28
MA(250): 1.86
MACD: MACD(12,26):
Signal(12,26,9): -0.01
%K %D: %K(14,3): 65.66
%D(3): 46.75
RSI: RSI(14): 62.26
52-Week: High: 3.58
Low: 1
Change(%): -52.9
Average Vol(K): 3-Month: 1793
10-Days: 990
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ VSTM ] has closed below upper band by 0.7%. Bollinger Bands are 30.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Mon, 08 Aug 2022
Verastem: Q2 Earnings Snapshot - The Advocate

Mon, 08 Aug 2022
2022-08-08 | NDAQ:VSTM | Press Release | Verastem Inc. - Stockhouse

Mon, 08 Aug 2022
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - The Bakersfield Californian

Wed, 27 Jul 2022
Is Verastem (NASDAQ:VSTM) Using Too Much Debt? - Yahoo Eurosport UK

Thu, 07 Jul 2022
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mon, 06 Jun 2022
Verastem VS-6766 shows promise in phase 2 ovarian cancer study - Seeking Alpha

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 186.36
% Held by Insiders 137400000.00
% Held by Institutions 0.97
Shares Short (K) 8160
Shares Short Prior Month (K)
Stock Financials
EPS -65570000.000
Book Value (p.s.)
Profit Margin
Operating Margin -2.00
Return on Assets (ttm) 993.1
Return on Equity (ttm) -32.5
Qtrly Rev. Growth 2200000.0
Gross Profit (p.s.) 205.325
Sales Per Share -108.312
EBITDA (p.s.) 787013.000
Qtrly Earnings Growth -0.41
Operating Cash Flow (M)
Levered Free Cash Flow (M) -53.47
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value
Price to Sales -0.01
Price to Cash Flow 2.53
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 4390000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android